ESR1 and breast neoplasm: Estrogen-ER binding also induces endothelial cell proliferation and migration opening the possibility of the use of ER competitors as possible antiangiogenic agents. Our group has previously demonstrated an estrogen induced enhanced expression of VEGF in vivo, thus, participating in neo-vascularization of estrogen responsive breast tumor tissues [15].